Bristol-Myers to acquire Adnexus for $430M

Bristol-Myers Squibb Co. said it will purchase biotech firm Adnexus Therapeutics for $430 million and up to $75 million in additional conditional payments, to help develop its class of drugs, called Adnectins, and expand the firm's investment in biologics. "We feel biologics will be a cornerstone of our future growth," a Bristol-Myers executive said.

View Full Article in:

Boston Globe (tiered subscription model), The · San Diego Union-Tribune

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR